Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Liver Neoplasms × Drug Evaluation × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 3 Breast Neoplasms 3 Lymphoma, Non-Hodgkin 2 Colorectal Neoplasms 2 Carcinoma, Basal Cell 2 Basal Cell Nevus Syndrome 2 Upper Tract Urothelial Carcinomas 1 Thrombocythemia, Essential 1 Solid Tumors 1 Serous Ovarian Cancer 1 Recurrence 1 Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1 Polycythemia Vera 1 Lymphedema 1 Liver Neoplasms 1 Leukemia 1 Immunoglobulin Light-chain Amyloidosis 1 Hypogonadism 1 Glioma 1 Fatigue Syndrome, Chronic 1 Fallopian Tube Neoplasms 1 Eunuchism 1 Carcinoma, Ovarian Epithelial 1 Breast Diseases 1 Amyloidosis 1 Adenoma 1

Interventions

Sorafenib 62 Bevacizumab 37 Oxaliplatin 25 Fluorouracil 21 Doxorubicin 19 Gemcitabine 18 durvalumab 17 Nivolumab 17 pembrolizumab 16 Radiosurgery 16 Radiofrequency Ablation 16 Cisplatin 16 lenvatinib 15 Leucovorin 14 Capecitabine 14 atezolizumab 12 Hepatectomy 12 Radiotherapy 11 tremelimumab 10 Irinotecan 10 Cyclophosphamide 10 Carboplatin 9 Blood Specimen Collection 9 Liver Transplantation 8 Ipilimumab 8 Drug Therapy 8 Cryosurgery 8 Chemotherapy, Adjuvant 8 fludarabine 7 Melphalan 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05913141 2023-06-22

PDO/PDO-TIL/PDOTS for Drug Screen

Shanghai Zhongshan Hospital

Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡